Brexanolone to Treat Postpartum Depression in Adult Women
Copyright © 1964–2019 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States..
ZULRESSO (Brexanolone) is a novel FDA-approved treatment for moderate-to-severe postpartum depression. Postpartum depression may be diagnosed in women experiencing depressive symptoms which can manifest as cognitive, behavioral, or emotional disturbances as early as the third trimester to 4 weeks following delivery. The efficacy of brexanolone suggests that neurosteroids such as allopregnanolone are important to treat PPD. However, it is currently unclear if brexanolone provides lasting relief of depressive symptoms at or beyond 30 days following administration. Further studies are necessary to make this determination.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:51 |
|---|---|
| Enthalten in: |
Psychopharmacology bulletin - 51(2021), 2 vom: 16. März, Seite 115-130 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cornett, Elyse M [VerfasserIn] |
|---|
| Themen: |
BXO86P3XXW |
|---|
| Anmerkungen: |
Date Completed 27.12.2021 Date Revised 11.11.2023 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM326410465 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326410465 | ||
| 003 | DE-627 | ||
| 005 | 20231225194532.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 028 | 5 | 2 | |a pubmed24n1087.xml |
| 035 | |a (DE-627)NLM326410465 | ||
| 035 | |a (NLM)34092826 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cornett, Elyse M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Brexanolone to Treat Postpartum Depression in Adult Women |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.12.2021 | ||
| 500 | |a Date Revised 11.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 1964–2019 by MedWorks Media Inc, Los Angeles, CA All rights reserved. Printed in the United States. | ||
| 520 | |a ZULRESSO (Brexanolone) is a novel FDA-approved treatment for moderate-to-severe postpartum depression. Postpartum depression may be diagnosed in women experiencing depressive symptoms which can manifest as cognitive, behavioral, or emotional disturbances as early as the third trimester to 4 weeks following delivery. The efficacy of brexanolone suggests that neurosteroids such as allopregnanolone are important to treat PPD. However, it is currently unclear if brexanolone provides lasting relief of depressive symptoms at or beyond 30 days following administration. Further studies are necessary to make this determination | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a GABA | |
| 650 | 4 | |a ZULRESSO | |
| 650 | 4 | |a brexanolone | |
| 650 | 4 | |a major depressive disorder | |
| 650 | 4 | |a postpartum depression | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a beta-Cyclodextrins |2 NLM | |
| 650 | 7 | |a brexanolone |2 NLM | |
| 650 | 7 | |a Pregnanolone |2 NLM | |
| 650 | 7 | |a BXO86P3XXW |2 NLM | |
| 700 | 1 | |a Rando, Lauren |e verfasserin |4 aut | |
| 700 | 1 | |a Labbé, Austin M |e verfasserin |4 aut | |
| 700 | 1 | |a Perkins, Wil |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Adam M |e verfasserin |4 aut | |
| 700 | 1 | |a Kaye, Alan David |e verfasserin |4 aut | |
| 700 | 1 | |a Viswanath, Omar |e verfasserin |4 aut | |
| 700 | 1 | |a Urits, Ivan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Psychopharmacology bulletin |d 1966 |g 51(2021), 2 vom: 16. März, Seite 115-130 |w (DE-627)NLM000009520 |x 2472-2448 |7 nnns |
| 773 | 1 | 8 | |g volume:51 |g year:2021 |g number:2 |g day:16 |g month:03 |g pages:115-130 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 51 |j 2021 |e 2 |b 16 |c 03 |h 115-130 | ||